Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 201–300 of 1,000
Wink, L. K., Adams, R., Wang, Z., Klaunig, J. E., Plawecki, M. H., Posey, D. J., McDougle, C. J., & Erickson, C. A. (2016) · Molecular Autism · doi:10.1186/s13229-016-0088-6 · Cited by 117
Self-citationZebrafish as a Model of Neurodevelopmental Disorders
de Abreu, M. S., Genario, R., Giacomini, A. C. V. V., Demin, K. A., Lakstygal, A. M., Amstislavskaya, T. G., Fontana, B. D., Parker, M. O., & Kalueff, A. V. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.034 · Cited by 100
Pervasive Developmental Disorder Not Otherwise Specified
Towbin, K. E. (2005) · Handbook of Autism and Pervasive Developmental Disorders · doi:10.1002/9780470939345.ch6 · Cited by 124
Langworthy-Lam, K. S., Aman, M. G., & Van Bourgondien, M. E. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602762599853 · Cited by 123
“…behavioral problems in autism is beginning to emerge; recently, the National Institute of Mental Health Autism Research Units of Pediatric Psychopharmacol-ogy Network reported major symptom reductions in children having both autistic disorder and high levels of irritability (McCracken et al. 2002).”
Self-citationAnagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1232 · Cited by 123
Self-citationInternet-Based, Randomized, Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism
Bent, S., Hendren, R. L., Zandi, T., Law, K., Choi, J.-E., Widjaja, F., Kalb, L., Nestle, J., & Law, P. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.01.018 · Cited by 112
“The rapid nature of the study compares favorably to traditional, clinic-based trials, including the landmark study of risperidone in 101 children with autism, which took 22 months to complete.(19) Although precise cost information from prior studies is not available, the cost of the IB-RCT method is likely substantial…”
ResultTreatment Incidence and Patterns in Children and Adolescents with Autism Spectrum Disorders
Witwer, A., & Lecavalier, L. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.671 · Cited by 125
Singer, H. S. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000752 · Cited by 138
Zuddas, A., Zanni, R., & Usala, T. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.001 · Cited by 131
Parikh, M. S., Kolevzon, A., & Hollander, E. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0041 · Cited by 120
Mahajan, R., Bernal, M. P., Panzer, R., Whitaker, A., Roberts, W., Handen, B., Hardan, A., Anagnostou, E., & Veenstra-VanderWeele, J. (2012) · Pediatrics · doi:10.1542/peds.2012-0900j · Cited by 121
Comai, S., Tau, M., Pavlovic, Z., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 120
Use of antipsychotics in children and adolescents.
Findling, R. L., Steiner, H., & Weller, E. B. (2005) · PubMed · Cited by 134
AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders
Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., Arnold, L. E., Posey, D., Young, C., Shah, B., et al. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.589 · Cited by 117
Self-citationPosey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.599 · Cited by 117
Self-citation(2012) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52002-9.00023-1 · Cited by 115
“The major tranquilizers (neuroleptics) have been most extensively studied and an elegant double-blind, placebo control study by the RUPP group demonstrated significant benefit of the atypical neuroleptic, risperidone, within two weeks (McCracken et al., 2002).”
BackgroundSelf-citationPharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research
Farmer, C., Thurm, A., & Grant, P. (2013) · Drugs · doi:10.1007/s40265-013-0021-7 · Cited by 115
A systems neuroscience approach to autism: Biological, cognitive, and clinical perspectives
Eigsti, I., & Shapiro, T. (2003) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10081 · Cited by 117
Fallah, M. S., Shaikh, M. R., Neupane, B., Rusiecki, D., Bennett, T. A., & Beyene, J. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0115 · Cited by 115
“Five trials were conducted in the United States (McCracken et al. 2002; Marcus et al. 2009; Owen et al. 2009; Kent et al. 2013; Loebel et al. 2016), one in Canada (Shea et al. 2004), one in Japan (Ichikawa et al. 2017), and one in Iran (Ghanizadeh et al. 2014).”
Hollway, J. A., & Aman, M. G. (2011) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2010.12.035 · Cited by 128
Self-citationLurasidone for the Treatment of Irritability Associated with Autistic Disorder
Loebel, A., Brams, M., Goldman, R. S., Silva, R., Hernandez, D., Deng, L., Mankoski, R., & Findling, R. L. (2016) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2628-x · Cited by 113
“It was estimated, based on results from two previous trials with other atypical agents (McCracken et al. 2002; Owen et al. 2009), that a sample size of 40 study partici-”
BackgroundResultInfluentialBringas, M. E., Carvajal-Flores, F. N., López-Ramírez, T. A., Atzori, M., & Flores, G. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.03.030 · Cited by 114
Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts
Budman, C., Coffey, B. J., Shechter, R., Schrock, M., Wieland, N., Spirgel, A., & Simon, E. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.061 · Cited by 99
Tsiouris, J. A. (2009) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2009.01232.x · Cited by 131
Factor Analysis of the Aberrant Behavior Checklist in Individuals with Autism Spectrum Disorders
Brinkley, J., Nations, L. D., Abramson, R. K., Hall, A., Wright, H. H., Gabriels, R. L., Gilbert, J. R., Pericak‐Vance, M. A., & Cuccaro, M. L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0327-3 · Cited by 125
Frazier, T. W., Shattuck, P. T., Narendorf, S. C., Cooper, B. P., Wagner, M., & Spitznagel, E. L. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0057 · Cited by 113
“In fact, the only FDA-approved medications for ASD, risperidone and aripiprazole, are indicated specifically for the treatment of irritability or aggression (McCracken et al. 2002; Shea et al. 2004; Marcus et al. 2009; Owen et al. 2009).”
Relaxation Response–Based Yoga Improves Functioning in Young Children with Autism: A Pilot Study
Rosenblatt, L. E., Gorantla, S., Torres, J. A., Yarmush, R. S., Rao, S., Park, E. R., Denninger, J. W., Benson, H., Fricchione, G. L., Bernstein, B., et al. (2011) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2010.0834 · Cited by 112
“32–34 Additionally, the aggregate scores of the ABC Irritability scale averaged with the BASC-2 scale scores showed highly significant post-treatment changes.”
The neuropathology, medical management and dental implications of autism
Friedlander, A. H., Yagiela, J. A., Paterno, V. I., & Mahler, M. E. (2006) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2006.0086 · Cited by 137
Bent, S., Lawton, B., Warren, T. L., Widjaja, F., Dang, K., Fahey, J. W., Cornblatt, B. S., Kinchen, J. M., Delucchi, K., & Hendren, R. L. (2018) · Molecular Autism · doi:10.1186/s13229-018-0218-4 · Cited by 118
“0 in the current study), respectively [27].”
Tartaglione, A. M., Schiavi, S., Calamandrei, G., & Trezza, V. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.024 · Cited by 130
Stigler, K. A., Potenza, M. N., Posey, D. J., & McDougle, C. J. (2004) · Pediatric Drugs · doi:10.2165/00148581-200406010-00003 · Cited by 114
Self-citationYui, K., Koshiba, M., Nakamura, S., & Kobayashi, Y. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182485791 · Cited by 109
Sensory and Motor Features in Autism: Assessment and Intervention
Baranek, G. T., Parham, L. D., & Bodfish, J. W. (2005) · Handbook of Autism and Pervasive Developmental Disorders · doi:10.1002/9780470939352.ch6 · Cited by 108
Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review
Seida, J. C., Schouten, J. R., Boylan, K., Newton, A. S., Mousavi, S. S., Beaith, A., Vandermeer, B., Dryden, D. M., & Carrey, N. (2012) · PEDIATRICS · doi:10.1542/peds.2011-2158 · Cited by 110
Kosillo, P., & Bateup, H. S. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.700968 · Cited by 127
Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., Gerhard, T., Olfson, M., & Correll, C. U. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.03.012 · Cited by 112
Ichikawa, H., Mikami, K., Okada, T., Yamashita, Y., Ishizaki, Y., Tomoda, A., Ono, H., Usuki, C., & Tadori, Y. (2017) · Child Psychiatry & Human Development · doi:10.1007/s10578-016-0704-x · Cited by 109
Autismo e doenças invasivas de desenvolvimento
Gadia, C. A., Tuchman, R. F., & Rotta, N. T. (2004) · Jornal de Pediatria · doi:10.1590/s0021-75572004000300011 · Cited by 419
Aripiprazole for Maladaptive Behavior in Pervasive Developmental Disorders
Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546042389118 · Cited by 109
Self-citationRoke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0120 · Cited by 109
“…of risperidone and olanzapine appear to be effective in the treatment of behavioral problems in autism spectrum disorders (Malone et al. 2002; McCracken et al. 2002), conduct disorders (Findling et al. 2000; Aman et al. 2002; Snyder et al. 2002), and acute psychotic symptoms (Arango et al.…”
Azmitia, E. C., Singh, J. S., & Whitaker-Azmitia, P. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.002 · Cited by 107
Aman, M. G., Findling, R. L., Hardan, A. Y., Hendren, R. L., Melmed, R. D., Kehinde-Nelson, O., Hsu, H.-A., Trugman, J. M., Palmer, R. H., Graham, S. M., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0146 · Cited by 106
Self-citationMazzone, L., Dooling, S. W., Volpe, E., Uljarević, M., Waters, J. L., Sabatini, A., Arturi, L., Abate, R., Riccioni, A., Siracusano, M., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.11.021 · Cited by 120
Rossignol, D. A., Rossignol, L. W., James, S. J., Melnyk, S., & Mumper, E. (2007) · BMC Pediatrics · doi:10.1186/1471-2431-7-36 · Cited by 108
Adler, B. A., Wink, L. K., Early, M. C., Shaffer, R. C., Minshawi, N. F., McDougle, C. J., & Erickson, C. A. (2014) · Autism · doi:10.1177/1362361314524641 · Cited by 114
“…subscale (ABC-I), which measures the severity of aggressive, selfinjurious, and tantrum behaviors, risperidone and aripiprazole have been FDA-approved for treatment of irritability in youth with autistic disorder (Blankenship et al., 2010; McCracken et al., 2002; Owen et al., 2009).”
BackgroundMethodSelf-citationSharma, A., & Shaw, S. R. (2011) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2011.02.008 · Cited by 124
Jensen, P. S., Buitelaar, J. K., Pandina, G., Binder, C. E., & Haas, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0580-1 · Cited by 115
“placebo) [45] or ‘‘abnormal movements’’ [46].”
BackgroundZiprasidone in Adolescents with Autism: An Open-Label Pilot Study
Malone, R. P., Delaney, M. A., Hyman, S. B., & Cater, J. R. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0126 · Cited by 104
The Dynamics of Autism Spectrum Disorders: How Neurotoxic Compounds and Neurotransmitters Interact
Quaak, I., Brouns, M., & Van de Bor, M. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10083384 · Cited by 101
“DOPAMINE: There is evidence that anomalies in the dopaminergic system are related to deficits as observed in subjects diagnosed with ASD [48].”
BackgroundHaas, M., Eerdekens, M., Kushner, S. F., Singer, J., Augustyns, I., Quiroz, J. A., Pandina, G., & Kusumakar, V. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046177 · Cited by 103
Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders
Francis, S. M., Sagar, A., Levin-Decanini, T., Liu, W., Carter, C. S., & Jacob, S. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.021 · Cited by 101
“…may be used for irritability, whereas guanfacine and clonidine are used off label for aggression, and selective serotonin reuptake inhibitors (SSRI; i.e. escitalopram, fluoxetine, and sertraline) are used to treat anxiety (Jaselskis et al., 1992; McCracken et al., 2002; Owley et al., 2010).”
BackgroundHuffman, L. C., Sutcliffe, T. L., Tanner, I. S. D., & Feldman, H. M. (2011) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3182040acf · Cited by 93
Mayes, S. D., Calhoun, S. L., Aggarwal, R., Baker, C. N., Mathapati, S., Anderson, R., & Petersen, C. A. (2011) · Research in Autism · doi:10.1016/j.rasd.2011.08.001 · Cited by 126
Quantitative assessment of autistic symptomatology in preschoolers
Pine, E., Luby, J., Abbacchi, A., & Constantino, J. N. (2006) · Autism · doi:10.1177/1362361306064434 · Cited by 100
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
“As a result of this increased vulnerability, non-adherence in youth is prompted by changes in their physical appearance leading to body image issues (58) and negative peer perception (59).”
BackgroundRodrigues, R., Lai, M., Beswick, A., Gorman, D. A., Anagnostou, E., Szatmari, P., Anderson, K. K., & Ameis, S. H. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13305 · Cited by 98
CD38 and its role in oxytocin secretion and social behavior
Higashida, H., Yokoyama, S., Kikuchi, M., & Munesue, T. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.011 · Cited by 98
Stigler, K. A., Diener, J. T., Kohn, A. E., Li, L., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.093 · Cited by 98
Self-citationVahabzadeh, A., Keshav, N. U., Abdus-Sabur, R., Huey, K., Liu, R., & Sahin, N. T. (2018) · Behavioral Sciences · doi:10.3390/bs8100085 · Cited by 91
“ABC-subscale changes of >25% have been used as a measure of response to treatment in a number of studies, including those focusing on irritability [22,23,43,67] and hyperactivity [43,69,72], and was also used as a measure of response to intervention in this study.”
BackgroundMethodInfluentialParent training for children with pervasive developmental disorders: a multi‐site feasibility trial
Research Units on Pediatric Psychopharmacology [RUPP] Autism Network (2007) · Behavioral Interventions · doi:10.1002/bin.236 · Cited by 96
Correia, C., Almeida, J. P., Santos, P. E., Sequeira, A. F., Marques, C., Miguel, T. S., Abreu, R., Oliveira, G. G., & Vicente, A. M. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.63 · Cited by 104
Geller, B., Tillman, R., Bolhofner, K., Zimerman, B., Strauss, N. A., & Kaufmann, P. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1130 · Cited by 96
Pavuluri, M. N., Henry, D. B., Carbray, J. A., Sampson, G., Naylor, M. W., & Janicak, P. G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.336 · Cited by 98
“Among the SGAs, risperidone has been extensively tested in pediatric populations and has been found to be safe (Armenteros et al. 1997; McCracken et al. 2002; Snyder et al. 2002; a et al. 2002; Buitelaar et al. 2001; Findling et al. 2000; Gaffney et al. 2002).”
Politte, L. C., & McDougle, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3068-y · Cited by 103
“The Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (McCracken et al. 2002) conducted a multi-site study that included an 8-week treatment phase followed by a 4-month open-label continuation phase and 2-month discontinuation phase.”
BackgroundMethodInfluentialSelf-citationMeasuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder
Scahill, L., Aman, M. G., Lecavalier, L., Halladay, A. K., Bishop, S. L., Bodfish, J. W., Grondhuis, S., Jones, N., Horrigan, J. P., Cook, E. H., et al. (2015) · Autism · doi:10.1177/1362361313510069 · Cited by 93
Self-citationNeural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders
Gandhi, T., & Lee, C. C. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592710 · Cited by 88
“It is an antagonist at the serotonin 2A and dopamine D2 receptors and is useful in alleviating irritability, aggression, and self-injurious behavior in young ASD subjects (McCracken et al., 2002; Shea et al., 2004; Chavez et al., 2006; Kent et al., 2013; Fung et al., 2016; Maneeton et al., 2018).”
BackgroundDietary Docosahexaenoic Acid Supplementation in Children With Autism
Voigt, R. G., Mellon, M. W., Katusic, S. K., Weaver, A. L., Matern, D., Mellon, B., Jensen, C. L., & Barbaresi, W. J. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000260 · Cited by 90
Gagliano, A., Germanò, E., Pustorino, G., Impallomeni, C., D’Arrigo, C., Calamoneri, F., & Spina, E. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454604773840472 · Cited by 95
“Consistent with some previous reports, our study indicated that risperidone brings about predominantly positive symptoms of autistic disorder, whereas it is less effective on negative ones (Masi et al. 2001b; McCracken et al. 2002; Zuddas et al. 2000).”
Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales
Barnes, K. V., Coughlin, F., O’Leary, H. M., Bruck, N. M., Bazin, G. A., Beinecke, E. B., Walco, A. C., Cantwell, N. G., & Kaufmann, W. E. (2015) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9127-4 · Cited by 96
“The ABC-C is the most widely employed measure of abnormal behavior in ID and autism spectrum disorder, with applications ranging from characterizing behavioral phenotype to measuring response to interventions [37–40].”
MethodTargeted treatments for symptom domains in child and adolescent autism
Hollander, E., Phillips, A., & Yeh, C.-C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14236-5 · Cited by 93
Autism Spectrum Disorders and commentaries
Lord, C., & Bishop, S. L. (2010) · Child Policy Nexus · doi:10.1002/j.2379-3988.2010.tb00063.x · Cited by 108
Controversies concerning the diagnosis and treatment of bipolar disorder in children
Parens, E., & Johnston, J. (2010) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-4-9 · Cited by 92
“Gabrielle Carlson offered the example of the atypical antipsychotic risperidone (Risperdal), which is effective at reducing aggression or rages in children diagnosed with BP–but is also effective in reducing aggression or rages in children with one or more disruptive behavior disorders (ADHD, ODD, and/or CD) and below…”
BackgroundSalazar de Pablo, G., Pastor Jordá, C., Vaquerizo-Serrano, J., Moreno, C., Cabras, A., Arango, C., Hernández, P., Veenstra-VanderWeele, J., Simonoff, E., Fusar-Poli, P., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.03.033 · Cited by 85
Deb, S., & Unwin, G. L. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282ab9952 · Cited by 94
Children with Schizophrenia: Clinical Picture and Pharmacological Treatment
Masi, G., Mucci, M., & Pari, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620100-00005 · Cited by 106
McQuire, C., Hassiotis, A., Harrison, B. A., & Pilling, S. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0688-2 · Cited by 110
“Sedation There were greater levels of sedation among children treated with risperidone [37, 41, 45, 48, 49] and aripiprazole [43, 44] than those who received placebo (RR = 0.”
BackgroundResultInfluentialAman, M., Rettiganti, M., Nagaraja, H. N., Hollway, J. A., McCracken, J., McDougle, C. J., Tierney, E., Scahill, L., Arnold, L. E., Hellings, J., et al. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0005 · Cited by 89
Self-citationAProspective, Open-Label Trial of Galantamine in Autistic Disorder
Nicolson, R., Craven-Thuss, B., & Smith, J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.621 · Cited by 89
A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation
Hellings, J. A., Zarcone, J. R., Reese, R. M., Valdovinos, M. G., Marquis, J. G., Fleming, K., & Schroeder, S. R. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0078-1 · Cited by 92
Bipolar disorder in adults with Asperger׳s Syndrome: A systematic review
Vannucchi, G., Masi, G., Toni, C., Dell’Osso, L., Erfurth, A., & Perugi, G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.042 · Cited by 101
Primary care for children with autism.
Carbone, P. S., Farley, M. A., & Davis, T. (2010) · PubMed · Cited by 109
Scahill, L., Jeon, S., Boorin, S. J., McDougle, C. J., Aman, M. G., Dziura, J., McCracken, J. T., Caprio, S., Arnold, L. E., Nicol, G., et al. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.02.016 · Cited by 85
Self-citationDrug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 97
Self-citationPractitioner Review: Psychopharmacology in children and adolescents with mental retardation
Handen, B. L., & Gilchrist, R. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01588.x · Cited by 88
Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism
Nishimura, K., Nakamura, K., Anitha, A., Yamada, K., Tsujii, M., Iwayama, Y., Hattori, E., Toyota, T., Takei, N., Miyachi, T., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.135 · Cited by 87
Randomized Controlled Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder
Connor, D. F., McLaughlin, T., & Jeffers-Terry, M. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0007 · Cited by 90
Comorbidity in Pediatric Bipolar Disorder
Joshi, G., & Wilens, T. E. (2009) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.12.005 · Cited by 94
Woodbury‐Smith, M., & Volkmar, F. R. (2008) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-008-0701-0 · Cited by 144
Self-citationCornish, K. M., Turk, J., Wilding, J., Sudhalter, V., Munir, F., Kooy, F., & Hagerman, R. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.t01-1-00297.x · Cited by 86
“The most commonly used atypical antipsychotic is risperidone, which also has documented efficacy in autism (McCracken, 2002), but weight gain is a significant side effect.”
BackgroundAn Update on Pharmacologic Treatments for Autism Spectrum Disorders
King, B. H., & Bostic, J. Q. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.005 · Cited by 92
Drug therapy in autism: a present and future perspective
Kumar, B., Prakash, A., Sewal, R. K., Medhi, B., & Modi, M. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70927-1 · Cited by 109
“Other side effects with use of risperidone include increased appetite, fatigue, dizziness and drowsiness [80].”
BackgroundRisperidone and Adaptive Behavior in Children With Autism
WILLIAMS, S. K., Scahill, L. D., Vitiello, B., Aman, M. G., Arnold, L. E., McDougle, C. J., McCracken, J. T., Tierney, E., Ritz, L., Posey, D. J., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000196423.80717.32 · Cited by 89
Self-citationConsoli, A., Cohen, J. P., Bodeau, N., Guinchat, V., Wachtel, L. E., & Cohen, D. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0320-7 · Cited by 85
“To date, risperidone [41–45], aripiprazole [46, 47] and divalproex [48] have been shown to be superior to placebo in reducing irritability and/or aggression.”
BackgroundTroost, P. W., Steenhuis, M.-P., Tuynman-Qua, H. G., Kalverdijk, L. J., Buitelaar, J. K., Minderaa, R. B., & Hoekstra, P. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.611 · Cited by 85
Munesue, T., Nakamura, H., Kikuchi, M., Miura, Y., Takeuchi, N., Anme, T., Nanba, E., Adachi, K., Tsubouchi, K., Sai, Y., et al. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00002 · Cited by 84
“In clinical settings, there are no effective treatments for the various symptoms of ASD, except for irritability, which can be alleviated by risperidone (11) or aripiprazole (12).”
BackgroundTreating the core features of autism: Are we there yet?
Bodfish, J. W. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20045 · Cited by 83
“…trials of atypical antipsychotics in autism, all reporting significant improvements in at least half of the patients studied [Findling et al., 1997; Horrigan and Barnhill, 1997; McDougle et al., 1997, 1998b; Potenza et al., 1999; Posey et al., 1999b; Malone et al., 2001; McCracken et al., 2002].”
A review of executive function deficits and pharmacological management in children and adolescents.
Hosenbocus, S., & Chahal, R. (2012) · Europe PMC (PubMed Central) · Cited by 141
Koenig, K. M., White, S. W., Pachler, M. C., Lau, M., Lewis, M., Klin, A., & Scahill, L. D. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0979-x · Cited by 104
Self-citationTreatment of inattention, overactivity, and impulsiveness in autism spectrum disorders
Aman, M. G., Farmer, C. A., Hollway, J., & Arnold, L. E. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.009 · Cited by 82
Self-citationPayakachat, N., Tilford, J. M., Kovacs, E. A., & Kuhlthau, K. A. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.29 · Cited by 96
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.